Preclinical studies has demonstrated that liraglutide enhances NK cell-mediated anti-tumor immune responses by inhibiting the IL-6/STAT3 signaling pathway in hepatocellular carcinoma cells and enhances NK cell functionality in obese patients [91]. Here, STAT3 is linked to neoplasm.